Crisaborole, also known as AN-2728, is a topically administered, boron-containing, anti-inflammatory compound that inhibits PDE4 activity and thereby suppresses the release of TNFalpha, IL-12, IL-23 and other cytokines. At the time of publication, three phase Ib clinical trials, a IIa trial and a IIb trial of AN-2728 in patients with psoriasis had been completed; the compound was also undergoing phase II development for atopic dermatitis, but no data were available for this indication.
Akama T, Baker SJ, Zhang YK, Hernandez V, Zhou H, Sanders V, Freund Y, Kimura R, Maples KR, Plattner JJ. Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2129-32. doi: 10.1016/j.bmcl.2009.03.007. Epub 2009 Mar 9. PubMed PMID: 19303290.
Baker, Stephen J.; Sanders, Virginia; Akama, Tsutomu; Bellinger-Kawahara, Carolyn; Freund, Yvonne; Maples, Kirk R.; Plattner, Jacob J.; Zhang, Yong-Kang; Zhou, Huchen; Hernandez, Vincent S. Boron-containing small molecules as anti-inflammatory agents. WO 2007095638. (Assignee Anacor Pharmaceuticals, Inc., USA)
Ceric, Helena; Malenica, Marica; Ratkaj, Marina; Landeka, Ivana; Jegorov, Alexandr. Solid state forms of crisaborole. US 20170305936.
Li, Peijie; Sun, Yuanchao; Zhang, Muqun; Du, Heng; Gao, Suwan; Hu, Zhenyu; Krivonos, Sonia; Khashper, Arkady; Shteinman, Vitaly; Sery, Yana; Ben-Daniel, Revital. Crisaborole production process. WO 2018150327. (Assignee Wavelength Enterprises Ltd., Israel)
Baker, Stephen J.; Akama, Tsutomu; Alley, Michael Richard Kevin; Benkovic, Stephen J.; Dipierro, Michael; Hernandez, Vincent S.; Hold, Karin M.; Kennedy, Isaac; Likhotvorik, Igor; Mao, Weimin; Maples, Kirk R.; Plattner, Jacob J.; Rock, Fernando; Sanders, Virginia; Stemphoski, Aaron M.; Yiannikouros, George Petros; Zegar, Siead; Zhang, Yong-Kang; Zhou, Huchen. Preparation of boron-containing small molecules and nucleosides for treating fungal infections. WO 2007078340. (Assignee Anacor Pharmaceuticals, Inc., USA)
Zhao, Xinhua. Synthetic method of crisaborole from 4-halogenated benzonitrile. CN 106928264. (Assignee Hunan Zhongzhi Youku Technology Co., Ltd., Peop. Rep. China)
Huguet Clotet, Juan; Ozores Viturro, Lidia; Rodriguez Ropero, Sergio; Dalmases Barjoan, Pere. Process for preparing 4-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl)oxy]benzonitrile (crisaborole). WO 2018115362. (Assignee Laboratorios Lesvi, SL, Spain)
Pullagurla, Manik Reddy; Pitta, Bhaskar Reddy; Namana, Suresh Babu; Rangisetty, Jagadeesh Babu. Novel process for the preparation of 4-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl)oxy]benzonitrile (crisaborole). WO 2018207216. (Assignee Biophore India Pharmaceuticals Pvt. Ltd., India)
Srinivasan, Thirumalai Rajan; Sajja, Eswaraiah; Ghojala, Venkat Reddy; Bekkam, Markandeya. Process for the preparation of 5-(4-cyanophenoxy)-1,3-dihydro-1-hydroxy-[2,1]-benzoxaborole and polymorphs thereof. WO 2018216032. (Assignee MSN Laboratories Private Limited, R&D Center, India)
Bhirud, Shekhar Bhaskar; Naik, Samir; Tewari, Amit; Kajale, Yogesh Baburao; Choraghe, Mahendra Joma; Pawar, Sanjay Sakharam. Process for preparation of crisaborole. WO 2018224923. (Assignee Glenmark Pharmaceuticals Limited, India)
